Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Auspex

- PMLiVE

FDA approves new drugs from Teva, Lilly and Elusys

Cinqair, Taltz and Anthim have all been given the green light in the US

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Teva Pharma logo

Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

Teva Pharma logo

TEVA buys Mexico’s RIMSA for $2.3bn

Follows acquisition ofAllergan’s generic drugs business

- PMLiVE

IBM teams up with Teva for global eHealth collaboration

Willalso partner with ICON on cancer trials project

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

- PMLiVE

Rebuffed Horizon tries to replace Depomed board members

But firm says latest deal 'significantly undervalues' Depomed

Teva Pharma logo

Teva takes controlling stake in genomics specialist

World’s largest generics firm takes deeper steps into patented medicines development

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

- PMLiVE

Teva buys Allergan generics unit for $40.5bn

Will now drop its six-month pursuit of Mylan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links